Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.
Latest from Edwin Elmhirst
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
A deep dive into sales expectations for individual pharma products reveals incretin agonists, immunology biologics and new formulations of established blockbusters dominating growth forecasts this year, with Merck & Co., Lilly, AbbVie and Bristol Myers Squibb particularly well positioned in 2026.
A Pink Sheet analysis found that of more than 87,000 written comments to a Vaccines and Related Biological Products Advisory Committee meeting docket, only a fraction were anti-vaccine, and many were the same or similar statements sent repeatedly.
Two familiar heavyweights of the obesity field return for another match, while four smaller companies are tipped to bring their own blockbusters to market, new data from Evaluate Pharma show.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.